[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@POWERLONG8 BioChef
BioChef posts on X about $til, $smmt, $bntx, to the the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXX +6,733%
- X Month XXX +3,275%
- X Months XXXXX -XX%
Mentions: X #
- X Month X no change
- X Months XX -XX%
Followers: XX #
- X Month XX +13%
- X Months XX +184%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence countries currencies
Social topic influence $til #2, $smmt #5, $bntx #1, to the, products, china, robust, strong
Top accounts mentioned or mentioned by @tradingsssss @lifescifocus @adar170 @amaymd @elonmusk @bkfviking123 @esgbiotech @andrewpannu @jacobplieth @sandman7591 @hbossnia @premium @anonym64382296 @maralgr @elysium55 @batman10023 @exbridgewater @pmdichristina @reidhuber @biotechtvhq
Top assets mentioned Summit Therapeutics Inc. Common Stock (SMMT)
Top Social Posts
Top posts by engagements in the last XX hours
"$TIL $SMMT $BNTX #immuneonco Group has submitted the application for Phase III clinical trial of IMM2510 for the treatment of immunotherapy (IO) resistant non-small cell lung cancer (NSCLC) and has recently submitted two Phase III clinical trials targeting different lung cancer to the Center for Drug Evaluation of National Medical Products Administration of the Peoples Republic of China (the NMPA)"
X Link 2025-12-10T17:19Z XX followers, XXX engagements
"$TIL $BNTX $SMMT #immuneonco Adding enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) to the PD-L1 VEGF and CD47 combination therapy significantly augments the anti-tumor response by adding a powerful direct tumor-killing mechanism via the innate immune system. This creates a more comprehensive and robust approach to cancer treatment"
X Link 2025-12-10T19:06Z XX followers, XXX engagements
"$TIL $SMMT $BNTX #Immuneonco now enrolling IMM01+IMM2510 PDL1 VEGF CD47"
X Link 2025-12-10T15:40Z XX followers, XXX engagements
"$TIL $SMMT $BNTX The benefit of combining IMM01 and IMM2510 for cancer treatment is the potential for a strong synergistic anti-tumor effect by targeting multiple mechanisms of tumor growth and immune evasion simultaneously"
X Link 2025-12-10T15:49Z XX followers, XXX engagements
"$TIL $SMMT #immuneonco The global CD47-SIRP(alpha ) inhibitors market size in 2024 stands at approximately $XXXX billion USD"
X Link 2025-12-10T21:28Z XX followers, XX engagements